These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33159496)

  • 1. Comparative biomarkers for HBsAg loss with antiviral therapy shows dominant influence of quantitative HBsAg (qHBsAg).
    Lim SG; Phyo WW; Ling JZJ; Cloherty G; Butler EK; Kuhns MC; McNamara AL; Holzmayer V; Gersch J; Yang WL; Ngu JH; Chang J; Tan J; Ahmed T; Dan YY; Lee YM; Lee GH; Tan PS; Huang DQ; Khine HTW; Lee C; Tay A; Chan E
    Aliment Pharmacol Ther; 2021 Jan; 53(1):172-182. PubMed ID: 33159496
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A critique and systematic review of the clinical utility of hepatitis B core-related antigen.
    Adraneda C; Tan YC; Yeo EJ; Kew GS; Khakpoor A; Lim SG
    J Hepatol; 2023 Apr; 78(4):731-741. PubMed ID: 36586590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching to or Add-on Peginterferon in Patients on Nucleos(t)ide Analogues for Chronic Hepatitis B: The SWAP RCT.
    Lim SG; Yang WL; Ngu JH; Chang J; Tan J; Ahmed T; Dan YY; Lim K; Lee YM; Lee GH; Tan PS; Wai KL; Phyo WW; Khine HHTW; Lee C; Tay A; Chan E
    Clin Gastroenterol Hepatol; 2022 Feb; 20(2):e228-e250. PubMed ID: 33895361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
    Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
    Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.
    Martinot-Peignoux M; Lapalus M; Maylin S; Boyer N; Castelnau C; Giuily N; Pouteau M; Moucari R; Asselah T; Marcellin P
    J Viral Hepat; 2016 Nov; 23(11):905-911. PubMed ID: 27375231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative anti-HBc combined with quantitative HBsAg can predict HBsAg clearance in sequential combination therapy with PEG-IFN-α in NA-suppressed chronic hepatitis B patients.
    Wang WX; Jia R; Gao YY; Liu JY; Luan JQ; Qiao F; Liu LM; Zhang XN; Wang FS; Fu J
    Front Immunol; 2022; 13():894410. PubMed ID: 35958609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hepatitis B virus core-related antigen and hepatitis B surface antigen for predicting HBeAg seroconversion in chronic hepatitis B patients with pegylated interferon therapy.
    Wang ML; Liao J; Wei B; Zhang DM; He M; Tao MC; Chen EQ; Tang H
    Infect Dis (Lond); 2018 Jul; 50(7):522-530. PubMed ID: 29463147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum hepatitis B core-related antigen as a surrogate marker of hepatitis B e antigen seroconversion in chronic hepatitis B.
    Chi XM; Wang XM; Wang ZF; Wu RH; Gao XZ; Xu HQ; Ding YH; Niu JQ
    World J Gastroenterol; 2021 Oct; 27(40):6927-6938. PubMed ID: 34790015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels.
    Rijckborst V; Hansen BE; Cakaloglu Y; Ferenci P; Tabak F; Akdogan M; Simon K; Akarca US; Flisiak R; Verhey E; Van Vuuren AJ; Boucher CA; ter Borg MJ; Janssen HL
    Hepatology; 2010 Aug; 52(2):454-61. PubMed ID: 20683945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.
    Tseng TC; Kao JH
    J Gastroenterol; 2013 Jan; 48(1):13-21. PubMed ID: 23090000
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir.
    Lee JM; Ahn SH; Kim HS; Park H; Chang HY; Kim DY; Hwang SG; Rim KS; Chon CY; Han KH; Park JY
    Hepatology; 2011 May; 53(5):1486-93. PubMed ID: 21520167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring of serum HBV RNA, HBcrAg, HBsAg and anti-HBc levels in patients during long-term nucleoside/nucleotide analogue therapy.
    Liao H; Liu Y; Li X; Wang J; Chen X; Zou J; Li Q; Liu L; Wang J; Huang B; Lu F; Xu D
    Antivir Ther; 2019; 24(2):105-115. PubMed ID: 30511941
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Follow-up and Quantitative Hepatitis B Surface Antigen Monitoring in North American Chronic HBV Carriers.
    O'Neil CR; Congly SE; Rose MS; Lee SS; Borman MA; Charlton CL; Osiowy C; Swain MG; Burak KW; Coffin CS
    Ann Hepatol; 2018; 17(2):232-241. PubMed ID: 31097238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis B virus RNA decline without concomitant viral antigen decrease is associated with a low probability of sustained response and hepatitis B surface antigen loss.
    Brakenhoff SM; de Man RA; Boonstra A; van Campenhout MJH; de Knegt RJ; van Bömmel F; van der Eijk AA; Berg T; Hansen BE; Janssen HLA; Sonneveld MJ
    Aliment Pharmacol Ther; 2021 Jan; 53(2):314-320. PubMed ID: 33222190
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum hepatitis B core-related antigen as a treatment predictor of pegylated interferon in patients with HBeAg-positive chronic hepatitis B.
    Chuaypen N; Posuwan N; Payungporn S; Tanaka Y; Shinkai N; Poovorawan Y; Tangkijvanich P
    Liver Int; 2016 Jun; 36(6):827-36. PubMed ID: 26678018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Outcomes and Quantitative HBV Surface Antigen Levels in Diverse Chronic Hepatitis B Patients in Canada: A Retrospective Real-World Study of CHB in Canada (REVEAL-CANADA).
    Coffin CS; Haylock-Jacobs S; Doucette K; Ramji A; Ko HH; Wong DK; Elkhashab M; Bailey R; Uhanova J; Minuk G; Tsoi K; Wong A; Ma MM; Tam E; Brahmania M; Nudo C; Zhu J; Lowe CF; Osiowy C; Lethebe BC; Congly SE; Chan EKH; Villasis-Keever A; Sbarigia U; Cooper CL; Fung S
    Viruses; 2022 Nov; 14(12):. PubMed ID: 36560672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum HBsAg quantification in treatment-naïve Indian patients with chronic hepatitis B.
    Ramachandran J; Ismail AM; Chawla G; Fletcher GJ; Goel A; Eapen CE; Abraham P
    Indian J Gastroenterol; 2014 Mar; 33(2):131-5. PubMed ID: 24052375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative HBeAg is a strong predictor of HBeAg loss among patients receiving pegylated interferon.
    Huang DQ; Shen L; Phyo WW; Cloherty G; Butler EK; Kuhns MC; McNamara AL; Holzmayer V; Gersch J; Anderson M; Yang WL; Ngu JH; Chang J; Tan J; Ahmed T; Dan YY; Lee YM; Lee GH; Tan PS; Muthiah M; Khine HTW; Lee C; Tay A; Lim SG
    Antiviral Res; 2024 Jul; 227():105876. PubMed ID: 38641023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B.
    Mak LY; Wong D; Kuchta A; Hilfiker M; Hamilton A; Chow N; Mao X; Seto WK; Yuen MF
    Clin Mol Hepatol; 2023 Jan; 29(1):146-162. PubMed ID: 35989092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis B core-related antigen reflects viral replication and protein production in chronic hepatitis B patients.
    Li J; Wu Z; Wang GQ; Zhao H
    Chin Med J (Engl); 2021 Mar; 134(10):1160-1167. PubMed ID: 33734135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.